The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Basiliximab has been a routine induction therapeutic agent even for well-matched living kidney transplantation(KT) with tacrolimus-based immunosuppression in Korea. As tacrolimus is a different drug from cyclosporine, the investigators study the usefulness of tacrolimus-based immunosuppression without basiliximab in well matched living KT.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asan Medical Center
• Treatments: Antibodies, Monoclonal; Basiliximab

Criteria

Inclusion Criteria:

• ABO compatible and T-flow negative transplants

• Living kidney transplantation

• Tacrolimus based immunosuppression

Exclusion Criteria:

• Multiorgan transplantation

• Zero-mismatch transplantation (we use cyclosporine instead of FK506)